ThromboGenics founder Désiré Collen to retire

9 December 2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR: BR) has announced that Désiré Collen has decided to retire as chairman and board member.

Staf Van Reet, a member of the ThromboGenics board and a seasoned biopharma veteran, has been appointed chairman of ThromboGenics.

Prof Collen played an instrumental role in ThromboGenics’ development and subsequent success since he founded the company in 1991. During his tenure as chief executive of ThromboGenics, the company started its research on Jetrea (ocriplasmin) and advanced it through its early clinical development for the treatment of symptomatic vitreomacular adhesion (VMA)/ vitreomacular traction (VMT). He was appointed ThromboGenics’ chairman at the founding of the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK